CINECA IRIS Institutional Research Information System

DE NICOLO', Amedeo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.748
EU - Europa 3.647
AS - Asia 1.463
SA - Sud America 58
AF - Africa 53
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 8
Totale 12.004
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.695
IT - Italia 801
CN - Cina 757
DK - Danimarca 579
IE - Irlanda 472
SE - Svezia 421
FR - Francia 265
SG - Singapore 260
AT - Austria 247
DE - Germania 167
UA - Ucraina 156
FI - Finlandia 155
GB - Regno Unito 123
VN - Vietnam 99
IN - India 93
KR - Corea 68
NL - Olanda 48
HK - Hong Kong 41
CA - Canada 39
JP - Giappone 37
BE - Belgio 35
ES - Italia 35
CZ - Repubblica Ceca 33
PL - Polonia 32
AU - Australia 26
BR - Brasile 24
TH - Thailandia 21
GR - Grecia 18
CL - Cile 16
EG - Egitto 16
RO - Romania 15
RU - Federazione Russa 13
MX - Messico 11
PK - Pakistan 11
TR - Turchia 11
ID - Indonesia 10
TW - Taiwan 10
ZA - Sudafrica 10
NG - Nigeria 9
UZ - Uzbekistan 9
CO - Colombia 8
EU - Europa 8
CH - Svizzera 7
SN - Senegal 6
IL - Israele 5
IQ - Iraq 5
PT - Portogallo 5
MY - Malesia 4
AE - Emirati Arabi Uniti 3
AR - Argentina 3
EC - Ecuador 3
NO - Norvegia 3
PS - Palestinian Territory 3
RS - Serbia 3
TN - Tunisia 3
HR - Croazia 2
HU - Ungheria 2
KZ - Kazakistan 2
LK - Sri Lanka 2
ME - Montenegro 2
MO - Macao, regione amministrativa speciale della Cina 2
MW - Malawi 2
PE - Perù 2
QA - Qatar 2
BD - Bangladesh 1
BF - Burkina Faso 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 12.004
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.314
Chandler 984
Dublin 471
Beijing 435
Fairfield 341
Torino 312
Houston 289
Woodbridge 251
Nyköping 221
Ashburn 211
Vienna 202
Dearborn 195
Villeurbanne 190
Wilmington 184
Singapore 183
Medford 141
Princeton 133
Cambridge 116
Seattle 116
Fremont 102
Redwood City 96
Jacksonville 94
Turin 87
New York 53
Boardman 48
Dong Ket 43
Milan 42
Boston 38
Pisa 37
Nanjing 35
Guangzhou 33
Shanghai 33
Washington 32
Hangzhou 29
Brussels 28
Brno 27
Santa Clara 24
Los Angeles 23
San Diego 23
Warsaw 23
Toronto 21
Hebei 19
Hefei 19
Norwalk 18
Chengdu 17
Hong Kong 17
Verona 16
Barcelona 13
Seoul 13
Helsinki 12
Munich 12
Tokyo 12
Genoa 11
Jinan 11
Mountain View 11
Rome 11
Cairo 10
Falls Church 10
Pune 10
Zhengzhou 10
Central District 9
Cinisello Balsamo 9
Hyderabad 9
Lappeenranta 9
London 9
Mumbai 9
Abuja 8
Edinburgh 8
Kunming 8
Nanchang 8
Silver Spring 8
Chicago 7
Des Moines 7
Phoenix 7
Taipei 7
Bangkok 6
Columbus 6
Jakarta 6
Medellín 6
Nola 6
Rio de Janeiro 6
Shenzhen 6
Tianjin 6
Athens 5
Bologna 5
Cape Town 5
Catania 5
Chongqing 5
Esslingen am Neckar 5
Falkenstein 5
Glasgow 5
Guiyang 5
Islamabad 5
Las Condes 5
Ottawa 5
Stockholm 5
Wuhan 5
Aachen 4
Andover 4
Bakersfield 4
Totale 7.764
Salva come PNG Salva come JPEG
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 392
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 387
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 241
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 232
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 215
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 212
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 191
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 187
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 185
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 174
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 173
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 169
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. 167
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 165
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 159
SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir 158
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 153
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 151
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 147
Antihypertensive Bridge Therapy by Continuous Drug Infusion with an Elastomeric Pump in Device-Resistant Hypertension 147
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 145
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 144
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 140
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 138
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 137
Quantification of tacrolimus in PBMCs samples in pediatric liver transplant patients and correlation with tacrolimus whole blood concentration 135
Pharmacokinetic and pharmacogenetic analysis of tacrolimus in pediatric liver transplant patients in the early post-liver transplantation period 133
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 133
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 131
Pharmacogenetics of ribavirin-induced anemia in HCV patients 130
An UPLC MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in Peripheral Blood Mononuclear Cells 129
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 125
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 122
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 120
Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study 117
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 115
Cannabinoids concentration variability in cannabis olive oil galenic preparations 115
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 114
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 107
Pharmacokinetics of Meropenem in Burn Patients with Infections Caused by Gram Negative Bacteria: Are We Getting Close to the Right Treatment? 106
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration 105
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 103
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 101
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 96
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 96
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 95
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 94
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 93
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. 91
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 90
Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients 89
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 88
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 86
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 83
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 83
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 83
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 83
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 78
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 78
An UPLC MS/MS method coupled with automated on-line solid phase extraction for quantification of tacrolimus in PBMC samples 75
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 75
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 75
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 74
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients 72
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 69
Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia 69
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 69
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 68
First UHPLC MS/MS method coupled with automated on-line SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients 68
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 66
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 66
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients 66
Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy 65
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 64
UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples 63
Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants 63
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients 62
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening 62
Pharmacogenetic of voriconazole antifungal agent in pediatric patients 61
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 60
UHPLC-MS/MS Method with On-line SPE to Quantify Tacrolimus and Everolimus in Peripheral Blood Mononuclear Cells: Application of “IS-normalized” Matrix Effect 59
Therapeutic drug monitoring guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence 58
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 57
A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring 57
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 56
UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients 56
A UHPLC-MS/MS Method to Quantify Tacrolimus in Tissues: Standardization Based on the Real Volume of Cells 56
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump 56
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 56
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma 56
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir. 54
Antiretroviral concentrations in the presence and absence of valproic acid 54
A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients 54
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 53
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 53
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 53
Totale 11.126
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.258
article - articoli 0
book - libri 0
conference - conferenze 5.764
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.022
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.881 0 0 49 138 183 369 168 110 180 258 193 233
2020/20211.453 164 75 50 90 116 104 107 52 105 115 191 284
2021/20222.447 176 193 196 196 156 213 181 152 114 129 388 353
2022/20232.773 249 234 71 258 253 659 164 230 315 61 182 97
2023/20241.127 154 194 78 54 64 152 28 51 13 59 108 172
2024/2025240 52 157 31 0 0 0 0 0 0 0 0 0
Totale 12.660